echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The Upstream and Downstream products of N-(4-Chloro-3-cyano-7-ethoxy-6-quinolinyl)acetamide

    The Upstream and Downstream products of N-(4-Chloro-3-cyano-7-ethoxy-6-quinolinyl)acetamide

    • Last Update: 2023-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    N-(4-Chloro-3-cyano-7-ethoxy-6-quinolinyl)acetamide, also known as Gleevec, is a widely used cancer medication that has been proven to effectively treat a variety of tumors, including chronic myeloid leukemia and gastrointestinal stromal tumors.
    In addition to its use as a cancer treatment, Gleevec is also used in the chemical industry as an intermediate in the production of other chemicals.


    One of the key applications of Gleevec in the chemical industry is as an intermediate in the production of agrochemicals.
    Gleevec is used as a precursor in the synthesis of certain types of herbicides and pesticides, which are used to protect crops from disease and pests.
    The use of Gleevec in the production of agrochemicals has been on the rise in recent years, due to its ability to improve crop yields and protect against losses due to pests and diseases.


    Another important application of Gleevec in the chemical industry is in the production of dyes and pigments.
    Gleevec is used as a precursor in the synthesis of certain types of dyes, which are used in a variety of applications, including textiles, plastics, and printing inks.
    The use of Gleevec in the production of dyes and pigments has been on the rise, due to its ability to provide a wide range of colors and its resistance to fading and degradation.


    Gleevec is also used in the production of other pharmaceuticals.
    The compound is used as an intermediate in the synthesis of certain types of antibiotics and antivirals, which are used to treat a variety of bacterial and viral infections.
    The use of Gleevec in the production of other pharmaceuticals has been on the rise, due to its ability to improve the efficacy and safety of these treatments.


    In addition to its use in the production of other chemicals and pharmaceuticals, Gleevec is also used in research and development.
    The compound is used in laboratory experiments as a tool to study the biology of cancer cells and to identify potential new targets for cancer treatments.
    The use of Gleevec in research and development has been on the rise, due to its ability to provide valuable insights into the biology of cancer and its potential to inform the development of new and more effective cancer treatments.


    Overall, N-(4-Chloro-3-cyano-7-ethoxy-6-quinolinyl)acetamide, also known as Gleevec, is an important intermediate in the production of a variety of chemicals and pharmaceuticals.
    The compound is widely used in the chemical industry and is also used in the production of other chemicals, dyes and pigments, and in research and development.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.